Proton pump inhibitors are not associated with an increased risk of colorectal cancer
Open Access
- 12 June 2020
- journal article
- research article
- Published by Hindawi Limited in GastroHep
- Vol. 2 (4) , 165-170
Abstract
Background The clinical relevance of proton pump inhibitors use as a risk factor for colorectal cancer in humans is still unclear. Aims To investigate the risk of colorectal cancer after the use of proton pump inhibitors within a linked Cancer Registry‐General Practitioner Database cohort. Methods Colorectal cancer patients diagnosed between 2007 and 2014 with at least 6 years of primary care data available prior to diagnosis (index date) were identified and matched to four controls on gender, birth year, general practice and period of primary care data availability. Proton pump inhibitor use was determined in the 6 years prior to the index date and analysed with conditional logistic regression, adjusted for potential confounders. Results 1041 cases (53%) and 4161 controls (53%) ever used a proton pump inhibitor, yielding an odds ratio (OR) of 1.08 (95% confidence interval (CI) 0.97‐1.21). Current use showed the highest OR (1.30 (95% CI 1.16‐1.47)). Long‐term use of proton pump inhibitors (≥4 years) was not associated with colorectal cancer (OR 0.92 (95% CI 0.76‐1.11)). A variation in OR for tumour stage and tumour subsite was observed with the highest OR for stage I tumour (1.28 (95% CI 0.87‐1.87)) and proximal colon (1.19 (95% CI 0.87‐1.63)). Conclusions No increased risk in colorectal cancer was seen with the use of proton pump inhibitors. Current use was associated with an increased likelihood to be diagnosed with colorectal cancer, but this is likely the result of reverse causality. No increased risk was seen for long‐term use of proton pump inhibitors.Keywords
This publication has 22 references indexed in Scilit:
- An overview of 25 years of incidence, treatment and outcome of colorectal cancer patientsInternational Journal of Cancer, 2018
- Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort studyPLOS ONE, 2017
- Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adultsThe Lancet, 2017
- Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump InhibitorsDigestive Diseases, 2017
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participantsThe Lancet, 2016
- Use of proton pump inhibitors correlates with increased risk of colorectal cancer in TaiwanAsia-Pacific Journal of Clinical Oncology, 2013
- Safety of Proton Pump Inhibitor ExposureGastroenterology, 2010
- Colorectal cancer risk in relation to use of acid suppressive medicationsPharmacoepidemiology and Drug Safety, 2009
- Chronic Proton Pump Inhibitor Therapy and the Risk of Colorectal CancerGastroenterology, 2007
- Autocrine Gastrins in Colon Cancer Cells Up-regulate Cytochromec Oxidase Vb and Down-regulate Efflux of Cytochromec and Activation of Caspase-3Journal of Biological Chemistry, 2000